Investigating novel drug combinations against patient-derived xenografts of acute lymphoblastic leukaemia

E Law, L McKenzie, K Szoltysek,J Lunec,J Irving, J Vormoor,O Heidenreich

Klinische Pädiatrie31. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch onkologische Forschung（2018）

引用 0|浏览1

暂无评分

摘要

Childhood acute lymphoblastic leukaemia (ALL) responds well to conventional treatment, however there is a need to find more targeted therapies without the associated toxicities. Assessment of drug combinations is costly and time consuming in vivo. The development of an in vitro ALL patient-derived xenograft (PDX)/mesenchymal stem cell (MSC) co-culture platform allows for screening of novel drug combinations in multiple ALL subtypes.

查看译文

关键词

Treatment Outcomes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要